Drug utilization study of mood stabilizers and antipsychotics drugs among bipolar disorder patients

Open Access

Issue		BIO Web Conf. Volume 148, 2024 International Conference of Biological, Environment, Agriculture, and Food (ICoBEAF 2024)


Article Number		01011
Number of page(s)		15
Section		Biological
DOI		https://doi.org/10.1051/bioconf/202414801011
Published online		09 January 2025

S. Chakrabarti, Bipolar disorder in the International Classification of Diseases-Eleventh version: A review of the changes, their basis, and usefulness., World J. Psychiatry 12, 1335 (2022) [CrossRef] [Google Scholar]
J. Spijker and S. Claes, [Mood disorders in the DSM-5]., Tijdschr. Psychiatr. 56, 173 (2014) [Google Scholar]
A. Kurumaji, [The trends of mood disorders in ICD-11: bipolar and depressive disorders]., Seishin Shinkeigaku Zasshi 115, 60 (2013) [PubMed] [Google Scholar]
N. Shah, S. Grover, and G.P. Rao, Clinical Practice Guidelines for Management of Bipolar Disorder., Indian J. Psychiatry 59, S51 (2017) [CrossRef] [Google Scholar]
A. Ertugrul and H. Y. Meltzer, Antipsychotic drugs in bipolar disorder., Int. J. Neuropsychopharmacol. 6, 277 (2003) [CrossRef] [Google Scholar]
I. Grande and E. Vieta, Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics?, CNS Drugs 29, 221 (2015) [CrossRef] [PubMed] [Google Scholar]
M. Sisay, G. Mengistu, B. Molla, F. Amare, and T. Gabriel, Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. BMC Health Serv. Res. 17, 161 (2017) [CrossRef] [Google Scholar]
H.J. Hamilton, P.F. Gallagher, and D. O’Mahony, Inappropriate prescribing and adverse drug events in older people., BMC Geriatr. 9, 5 (2009) [Google Scholar]
R. Ofori-Asenso and A. Agyeman, Irrational Use of Medicines—A Summary of Key Concepts, Pharmacy 4, 35 (2016) [CrossRef] [PubMed] [Google Scholar]
E.P. Ivanova, V.K. Truong, J.Y. Wang, C.C. Berndt, R.T. Jones, I.I. Yusuf, I. Peake, H. W. Schmidt, C. Fluke, D. Barnes, and R. J. Crawford, Guidelines for ATC classification and DDD assignment, Guidelines for ATC Classification and DDD Assignment (2010) [Google Scholar]
WHO, Guidelines for ATC classification and DDD assignment 2013, Guidelines for ATC Classification and DDD Assignment 2013, 14th ed. (WHO Collaborating Centre for Drug Statistics Methodology, Oslo, 2013) [Google Scholar]
K. Sharifi, M. Anoosheh, M. Foroughan, and A. Kazemnejad, Barriers to Middle-Aged Women’s Mental Health: A Qualitative Study., Iran. Red Crescent Med. J. 16, e18882 (2014) [Google Scholar]
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017., Lancet (London, England) 392, 1789 (2018) [Google Scholar]
R.C. Kessler, T.C. Wai, O. Demler, and E.E. Walters, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617 (2005) [CrossRef] [PubMed] [Google Scholar]
L. Fu-I, [Bipolar disorder in childhood and adolescence]., Rev. Bras. Psiquiatr. 26 Suppl 3, 22 (2004) [Google Scholar]
D. Prabhakar and R. Balon, Late-onset bipolar disorder: a case for careful appraisal., Psychiatry (Edgmont). 7, 34 (2010) [Google Scholar]
C. V Calkin, D.M. Gardner, T. Ransom, and M. Alda, The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders., Ann. Med. 45, 171 (2013) [CrossRef] [PubMed] [Google Scholar]
C. Hamal et al., Metformin for the improvement of comorbid depression symptoms in diabetic patients: A Systematic Review., Cureus 14, e28609 (2022) [PubMed] [Google Scholar]
H. K. Schoeyen et al., Bipolar disorder patients have similar levels of education but lower socio-economic status than the general population., J. Affect. Disord. 129, 68 (2011) [CrossRef] [Google Scholar]
D. DiBenedetti, K. Kosa, H. C. Waters, and D. Oberdhan, Understanding patients’ experiences with borderline personality disorder: Qualitative interviews., Neuropsychiatr. Dis. Treat. 19, 2115 (2023) [CrossRef] [Google Scholar]
S.-J. Lu et al., Predictors of employment status for persons with bipolar disorder., Int. J. Environ. Res. Public Health 19, (2022) [Google Scholar]
L. Culpepper, The diagnosis and treatment of bipolar disorder: decision-making in primary care., Prim. Care Companion CNS Disord. 16, (2014) [Google Scholar]
G.F. Johnson and G.E. Hunt, Onset of mania in bipolar manic-depressive patients., Aust. N. Z. J. Psychiatry 13, 57 (1979) [CrossRef] [PubMed] [Google Scholar]
L.V. Kessing, Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice., Int. J. Bipolar Disord. 12, 3 (2024) [CrossRef] [Google Scholar]
M. Gitlin, Lithium side effects and toxicity: prevalence and management strategies., Int. J. Bipolar Disord. 4, 27 (2016) [CrossRef] [Google Scholar]
R. Lozano, R. Marín, and M.-J. Santacruz, Influence of hypothyroidism on renal function of lithium-treated patients., Neuropsychiatr. Dis. Treat. 12, 25 (2016) [Google Scholar]
M.C. Smith, F. Centorrino, J.A. Welge, and M.A. Collins, Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials., Epilepsy Behav. 5, 746 (2004) [CrossRef] [PubMed] [Google Scholar]
J.M. Goikolea, F. Colom, J. Capapey, I. Torres, M. Valenti, I. Grande, J. Undurraga, and E. Vieta, Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania, Eur. Neuropsychopharmacol. 23, 305 (2013) [Google Scholar]
G. Ostuzzi et al., Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants., World Psychiatry 21, 295 (2022) [CrossRef] [PubMed] [Google Scholar]
E. Vieta and J. Sanchez-Moreno, Acute and long-term treatment of mania., Dialogues Clin. Neurosci. 10, 165 (2008) [CrossRef] [Google Scholar]
M. Holm, A. Tanskanen, M. Lähteenvuo, J. Tiihonen, and H. Taipale, Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder, Eur. Neuropsychopharmacol. 61, 36 (2022) [CrossRef] [Google Scholar]
T. Ali, M. Sisay, M. Tariku, A. N. Mekuria, and A. Desalew, Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies., PLoS One 16, e0257129 (2021) [CrossRef] [PubMed] [Google Scholar]
A. Baslam, H. Azraida, R. Aboufatima, M. Ait-El-Mokhtar, I. Dilagui, S. Boussaa, A. Chait, and M. Baslam, Trihexyphenidyl Alters Its Host’s Metabolism, Neurobehavioral Patterns, and Gut Microbiome Feedback Loop—The Modulating Role of Anacyclus pyrethrum, Antioxidants 13, (2024) [Google Scholar]
M. J. Gitlin, Antidepressants in bipolar depression: an enduring controversy., Int. J. Bipolar Disord. 6, 25 (2018) [CrossRef] [Google Scholar]
H.-P. Tsai et al., Risperidone exacerbates glucose intolerance, nonalcoholic fatty liver disease, and renal impairment in obese mice., Int. J. Mol. Sci. 22, (2021) [Google Scholar]
D.A. Sykes, H. Moore, L. Stott, N. Holliday, J. A. Javitch, J.R. Lane, and S.J. Charlton, Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors., Nat. Commun. 8, 763 (2017) [CrossRef] [Google Scholar]
J. Orzelska-Górka, J. Mikulska, A. Wiszniewska, and G. Biała, New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression., Int. J. Mol. Sci. 23, (2022) [Google Scholar]
C. Sanderson, C. Swenson, and M. Bohus, American Psychiatric Association Practice Guideline for the Treatment of Patiens with Bipolar Disorder, J. Pers. Disord. 16, 122 (2002) [CrossRef] [PubMed] [Google Scholar]
R. J. Leo and R. Narendran, Anticonvulsant Use in the treatment of bipolar disorder: A primer for primary care physicians., Prim. Care Companion J. Clin. Psychiatry 1, 74 (1999) [Google Scholar]
E. Grandjean and J.-M. Aubry, Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring, CNS Drugs 23, 331 (2009) [Google Scholar]
S. Subramanian, B.A. Völlm, and N. Huband, Clozapine dose for schizophrenia., Cochrane Database Syst. Rev. 6, CD009555 (2017). [Google Scholar]
L. Gyulai et al., Maintenance efficacy of divalproex in the prevention of bipolar depression., Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 28, 1374 (2003) [CrossRef] [PubMed] [Google Scholar]
R.C. Reed, S. Dutta, and W. Liu, Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy., Epilepsy Res. 87, 260 (2009) [CrossRef] [Google Scholar]
S. Dutta, Y. Zhang, D.S. Selness, L.L. Lee, L.A. Williams, and K.W. Sommerville, Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers, Epilepsy Res. 49, 1 (2002) [CrossRef] [Google Scholar]
A.P.M. Kerckhoffs, E.G.T.M. Hartong, and K.P. Grootens, The perspectives of patients with lithium-induced end-stage renal disease., Int. J. Bipolar Disord. 6, 13 (2018) [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.